Details for Patent: 7,612,114
✉ Email this page to a colleague
Which drugs does patent 7,612,114 protect, and when does it expire?
Patent 7,612,114 protects ORSERDU and is included in one NDA.
This patent has six patent family members in five countries.
Drugs Protected by US Patent 7,612,114
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 7,612,114 | ⤷ Subscribe | Y | Y | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Subscribe | ||
| Stemline Therap | ORSERDU | elacestrant dihydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 7,612,114 | ⤷ Subscribe | Y | Y | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,612,114
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2003292625 | ⤷ Subscribe | |||
| Canada | 2512000 | ⤷ Subscribe | |||
| European Patent Office | 1577288 | ⤷ Subscribe | |||
| Japan | 4500689 | ⤷ Subscribe | |||
| Japan | WO2004058682 | ⤷ Subscribe | |||
| World Intellectual Property Organization (WIPO) | 2004058682 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
